Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Caredx Inc (CDNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 866,584
  • Shares Outstanding, K 36,350
  • Annual Sales, $ 48,320 K
  • Annual Income, $ -55,470 K
  • 36-Month Beta 0.92
  • Price/Sales 16.45
  • Price/Cash Flow N/A
  • Price/Book 26.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.30 +19.60%
on 10/16/18
29.60 -13.92%
on 09/27/18
-0.56 (-2.15%)
since 09/17/18
3-Month
11.93 +113.58%
on 07/30/18
29.60 -13.92%
on 09/27/18
+12.93 (+103.03%)
since 07/17/18
52-Week
4.92 +417.89%
on 01/17/18
29.60 -13.92%
on 09/27/18
+19.59 (+332.60%)
since 10/17/17

Most Recent Stories

More News
CareDx to Announce Third Quarter 2018 Financial Results on November 8, 2018

CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,...

CDNA : 25.48 (+6.88%)
CareDx Profiles AlloSeq Suite of NGS Products at ASHI

Expands portfolio with three new kitted transplant products launching in 2019

CDNA : 25.48 (+6.88%)
CareDx to Participate in Upcoming Investor Conference

CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,...

CDNA : 25.48 (+6.88%)
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

ARWR : 13.49 (-2.74%)
DWAS : 52.03 (-0.40%)
CDNA : 25.48 (+6.88%)
INGN : 212.35 (+0.17%)
CareDx broadens HeartCare availability

CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,...

CDNA : 25.48 (+6.88%)
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

DWAS : 52.03 (-0.40%)
CDNA : 25.48 (+6.88%)
MRTX : 42.18 (-4.09%)
PLUS : 87.46 (-1.18%)
CareDx to Participate in Upcoming Investor Conference

CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,...

CDNA : 25.48 (+6.88%)
Teladoc (TDOC) Hits 52-Week High, Will the Rally Continue?

Strong second-quarter earnings performance and favorable guidance pulled up the stock of Teladoc (TDOC).

TDOC : 69.95 (-1.30%)
CDNA : 25.48 (+6.88%)
PRAH : 103.26 (-0.46%)
OPGN : 1.69 (-9.14%)
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of 20.00% and 16.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CDNA : 25.48 (+6.88%)
CareDx Reports Second Quarter Results

AlloSure launch momentum drives 48% revenue growth

CDNA : 25.48 (+6.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CDNA with:

Business Summary

CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of...

See More

Key Turning Points

2nd Resistance Point 26.86
1st Resistance Point 26.17
Last Price 25.48
1st Support Level 24.30
2nd Support Level 23.12

See More

52-Week High 29.60
Last Price 25.48
Fibonacci 61.8% 20.17
Fibonacci 50% 17.26
Fibonacci 38.2% 14.35
52-Week Low 4.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar